SVRA earnings analysis
What we found in SVRA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Savara remains a pre-revenue, single-program biotech with no disclosed revenue, a second-quarter net loss of $40.2 million and six-month operating cash use of $62.8 million. Liquidity was approximately $173.0 million at June 30, 2026, but management expects continued losses and may need additional capital. Regulatory progress for MOLBREEVI is constructive, although the FDA extended the PDUFA date to November 22, 2026, preserving substantial approval and commercialization risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- MOLBREEVI remains under priority review
- The FDA formally filed the MOLBREEVI BLA and granted Priority Review in February 2026; the FDA subsequently extended the PDUFA target action date by three months to November 22, 2026.
- $173.0M liquidity position
- Cash, cash equivalents and short-term investments totaled approximately $173.0 million at June 30, 2026, including $41.8 million of cash and cash equivalents and $131.2 million of short-term investments.
- Investments offset operating cash burn
- Six-month cash used in operating activities was $62.8 million, while investing activities provided $71.4 million, primarily from maturities and activity in short-term investments; net cash increased by $8.6 million.
- Commercial launch infrastructure advancing
- Management is building commercial infrastructure ahead of a planned product launch: second-quarter G&A expense increased 78.2% year over year to $19.0 million, including $7.5 million of higher personnel costs.
- European regulatory submissions validated
- MOLBREEVI submissions have also advanced in Europe and the U.K.; the EMA validated the MAA in March 2026 and the MHRA validated the U.K. MAA in April 2026 with a 150-day accelerated assessment.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses continue to widen
- Second-quarter net loss increased to $40.2 million from $30.4 million in the prior-year quarter, while six-month net loss reached $77.5 million versus $57.0 million in the prior-year period.
- Rising cash burn
- Operating cash use increased to $62.8 million in the six months ended June 30, 2026 from $53.5 million in the prior-year period. Management expects significant additional expenses and operating losses for at least the next several years.
- Approval and commercialization dependency
- Savara has no product revenue and stated it does not know when, or if, product revenue will begin. Revenue depends on regulatory approval and commercialization of MOLBREEVI, whose FDA action date was extended to November 22, 2026.
- Potential need for additional capital
- Management stated that additional capital may be needed to fund development, regulatory approvals and commercialization, despite approximately $173.0 million of cash, cash equivalents and short-term investments at June 30, 2026.
- Development and manufacturing costs
- Second-quarter research and development expense rose 5.8% year over year to $22.0 million, and management expects R&D spending to remain significant, including investment in a second-source manufacturer and CMC supplies.
- Debt access depends on approval
- The Hercules Loan Agreement provides for up to $105.0 million, but future tranches are subject to conditions including FDA approval; the facility carried an 8.2% interest rate at June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Segment
- Single operating segment; no product revenue has been generated from inception through June 30, 2026
What they said about what is next.
No explicit numeric revenue or EPS guidance was provided. Management stated it does not expect product revenue unless and until MOLBREEVI receives regulatory approval and is commercialized. The FDA PDUFA target action date is November 22, 2026, following a three-month extension.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 12, 2026
- Savara Inc. reported a significant net loss of $37.3 million for Q1 2026, compared to a loss of $26.6 million in Q1 2025. Operating expenses rose by 37.2% year-over-year due to increased R&D and G&A costs. The company's…
- 10-K · March 13, 2026
- Savara Inc., a clinical-stage biopharmaceutical company focused on autoimmune pulmonary diseases, reported an operating loss of $123.5 million for the year ended December 31, 2025, an increase from $103.2 million in…
- 10-Q · November 12, 2025
- Savara Inc. reported a net loss of $29.6 million for Q3 2025, an increase from the previous year's loss of $24.2 million, reflecting continued challenges with revenue generation as the company reported zero revenue.…
- 10-Q · August 13, 2025
- Savara Inc. reported a net loss of $30.4 million for Q2 2025, an increase from $22.2 million in Q2 2024. The company continues to have no revenue, reflecting ongoing research and development costs primarily related to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SVRA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever